INTRODUCTION RESULTS
• Results from this preliminary real-world analysis are consistent with those from the phase III MPACT trial and provide evidence for the effectiveness of nab-P/G in 1L mPCa
• Although there are recognized, common limitations to EHR data, sufficient clinical information could be abstracted to answer clinical questions in a prespecified patient population
• Additional evaluations are underway to further assess the ability of an EHR system to accurately capture critical information that would be vital to a longitudinal, prospective cohort study
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nab-P/G treatment within 30 days after diagnosis of metastatic disease) to evaluate potential survival bias from the 60-day treatment initiation inclusion criterion
• Endpoints are described in Table 1 • 1L nab-P/G treatment duration was measured from date of first administration of either nab-P or G until the last administration date + 7 days or last visit date, whichever was later, but was not to exceed the date of death
Endpoint Definition

OS
Start date of 1L nab-P/G treatment to the date of death; patients who were still alive were censored at the last contact date before or on the data cutoff of 31 January 2017
PFS
Start date of 1L nab-P/G treatment to the earliest date of documented disease progression or death; patients who were still alive or without PD were censored at the last contact date before or on the data cutoff of 31 January 2017
Treatment Duration and Clinical Outcomes
• Median duration of 1L nab-P/G treatment was 4.4 months • Of those who discontinued 1L treatment prior to the data cutoff (n = 182), the most common reasons were disease progression (69%) and toxicity (13%)
• PFS and OS are summarized in Figures 3 and 4 (A and B) , respectively -A sensitivity analysis revealed that both PFS and OS were similar between all patients and those who received 1L nab-P/G within 30 days of mPCa diagnosis
STRENGTHS AND LIMITATIONS
• The Flatiron Health EHR database represents one of the largest communitybased oncology EHR databases in the United States
• A real-world population, such as that presented herein, is likely more representative of the general mPCa population than patients enrolled in a clinical trial
• The median age in this study (68 years) is higher than that of patients in the MPACT trial (63 years) 2 and is closer to the median age of patients diagnosed with all stages of pancreatic cancer (70 years) 3 • Limitations to EHR studies may include missing or erroneous data and/or bias due to a lack of protocol-mandated treatment and response criteria -Missing data  Electronic medical record (EMR) structured data fields are not always completed. For example, in this study (and similar to other real-world data sets), ECOG PS data were missing for 42% of patients -Gaps in follow-up and loss to follow-up (LTFU) can potentially bias or weaken outcome analyses  Patients may be referred in and out of the EMR network  An LTFU of 20% or higher in observational studies is not uncommon;
however, 72% of deaths were captured as of the data cutoff (31 January 2017)
• Currently, there is no universal set of standardized definitions in real-world oncology studies, thus limiting comparisons across studies -Definitions of line of therapy and disease progression as well as laboratory tests or reasons for stopping treatment must be derived from available data, and algorithms must be applied based on assumptions 
